GEROPHARM
Private Company
Funding information not available
Overview
GEROPHARM has evolved from a domestic player into a significant, vertically integrated biotech company and the market leader for insulin in Russia. Its strategy is built on mastering complex biotechnologies, particularly for insulin and biosimilars, and expanding its international footprint through exports and local production partnerships. With over $160 million invested in R&D and innovation in the past decade and two major manufacturing sites, the company is positioned to capitalize on import substitution policies and growing demand in emerging markets.
Technology Platform
Full-cycle biopharmaceutical development and manufacturing platform specializing in recombinant protein (insulin) production and biosimilar development, with capabilities in peptide-based drug and generic small molecule development. Operates in-house R&D center and two GMP manufacturing plants.
Pipeline
23| Drug | Indication | Stage | Watch |
|---|---|---|---|
| GP40071 + NovoRapid® Penfill® | Diabetes | Phase 3 | |
| GP40081 + NovoMix 30 | Diabetes Mellitus, Type 2 | Phase 3 | |
| GP404141 + Nplate | Drug Effect | Phase 3 | |
| Humalog Mix25 + Insulin Lispro Biphasic 25 | Diabetes Mellitus, Type 2 | Phase 3 | |
| Lantus Solostar, 100 Units/mL Subcutaneous Solution + Insuli... | Diabetes Mellitus, Type 1 | Phase 3 |
Opportunities
Risk Factors
Competitive Landscape
In Russia, competes as the insulin market leader against multinationals (like Novo Nordisk, Sanofi) and local producers. Internationally, positions as a cost-competitive supplier of biosimilar insulins and biotech medicines in emerging markets, competing with other generics/biosimilars manufacturers from India, China, and the Middle East.